With $60 Billion in brand-name drug revenues set to evaporate over the next five years, pharma companies are paying more attention to patient retention in categories that are going generic.
More Generics Slow Rise in Drug Prices - New York Times
With $60 Billion in brand-name drug revenues set to evaporate over the next five years, pharma companies are paying more attention to patient retention in categories that are going generic.
More Generics Slow Rise in Drug Prices - New York Times